Swiss National Bank Keros Therapeutics, Inc. Transaction History

Swiss National Bank

$140 Billion
Q1 2024

A detailed history of Swiss National Bank transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 49,900 shares of KROS stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,900

Previous 40,900 22.0%

Holding current value

$2.28 Million

Previous $1.63 Million 103.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$41.26 - $70.48 $371,340 - $634,320	9,000 Added 22.0%	49,900 $3.3 Million
Q4 2023 Feb 06, 2024	SELL	$27.12 - $41.05 $127,464 - $192,935	-4,700 Reduced 10.31%	40,900 $1.63 Million
Q3 2023 Nov 08, 2023	BUY	$31.57 - $43.02 $66,297 - $90,342	2,100 Added 4.83%	45,600 $1.45 Million
Q2 2023 Aug 09, 2023	BUY	$37.26 - $51.01 $290,628 - $397,878	7,800 Added 21.85%	43,500 $1.75 Million
Q1 2023 May 10, 2023	SELL	$41.44 - $59.32 $66,304 - $94,912	-1,600 Reduced 4.29%	35,700 $1.52 Million

Q4 2022 Feb 08, 2023	BUY	$39.45 - $51.77 $122,295 - $160,487	3,100 Added 9.06%	37,300 $1.79 Million
Q3 2022 Nov 09, 2022	BUY	$27.8 - $40.12 $30,580 - $44,132	1,100 Added 3.32%	34,200 $1.29 Million
Q2 2022 Aug 09, 2022	BUY	$26.03 - $67.04 $70,281 - $181,008	2,700 Added 8.88%	33,100 $915,000
Q1 2022 May 09, 2022	BUY	$42.12 - $59.36 $96,876 - $136,528	2,300 Added 8.19%	30,400 $1.65 Million
Q2 2021 Aug 06, 2021	BUY	$42.4 - $70.11 $318,000 - $525,825	7,500 Added 36.41%	28,100 $1.19 Million
Q4 2020 Feb 05, 2021	BUY	$36.0 - $82.74 $741,600 - $1.7 Million	20,600 New	20,600 $1.45 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Keros Therapeutics, Inc. Transaction History